Luhan Pharmachem Co., Ltd.

Luhan pharmachem Co., Ltd. supplies Vincristine Sulfate bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Vincristine Sulfate is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Vincristine Sulfate?

Vincristine Sulfate, a dimeric Vinca alkaloid, site has been shown to bind to Tubulin via a protein self association reaction. This compound acts as a Tubuiln inhibitor by binding to sites at the ends of microtubules, no rx which regulate the inhibition of Tubulin dimer addition to microtubule ends. Experiments have reported Vincristine Sulfate to demonstrate a capacity to suppress growth of proliferating cells through marked apoptosis. The cell death caused by this agent seems to result in a sustained accumulation of endogenous ceramide levels. Ceramide has been proposed as a lipid second messenger with specific antiproliferative mediating responses. Vincristine Sulfate is an inhibitor of MAO. Vincristine Sulfate is also a substrate of PGP and CYP3A4.

More  information

CAS No.:2068-78-2

Indications

Vincristine sulfate is approved to treat:

• Acute leukemia.

Vincristine sulfate is sometimes used to treat other types of cancer, including:

• Hodgkin lymphoma.
• Neuroblastoma.
• Non-Hodgkin lymphoma (NHL).
• Rhabdomyosarcoma.
• Wilms tumor.

Vincristine sulfate is also being studied in the treatment of other types of cancer.

Pharmacodynamics

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin’s disease, Kaposi’s sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumor properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

What is the mechanism of action?

The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with:

1) amino acid, cyclic AMP, and glutathione metabolism,

2) calmodulin-dependent Ca2+-transport ATPase activity,

3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.

Dosage and administration of Vincristine Sulfate

The concentration of Vincristine Sulfate Injection, USP (vincristine sulfate) is 1 mg/ml. Do not add extra fluid to the vial prior to removal of the dose. Withdraw the solution of Vincristine Sulfate Injection, USP (vincristine sulfate) into an accurate dry syringe, measuring the dose carefully. Do not add extra fluid to the vial in an attempt to empty it completely.

Vincristine Sulfate Injection, USP (vincristine sulfate) must be administered via an intact, free-flowing intravenous needle or catheter. Care should be taken that there is no leakage or swelling occurring during.

The solution may be injected either directly into a vein or into the tubing of a running intravenous infusion. Injection of Vincristine Sulfate Injection, USP (vincristine sulfate) should be accomplished within 1 minute.

What are the side effects of Vincristine Sulfate?

In general, adverse reactions are reversible and are related to dosage. The most common adverse reaction is hair loss; the most troublesome adverse reactions are neuromuscular in origin.

Although most such symptoms usually disappear by about the sixth week after discontinuance of treatment, some neuromuscular difficulties may persist for prolonged periods in some patients. Regrowth of hair may occur while maintenance therapy continues.

Storage

Store Vincristine Sulfate at -20 degrees Celsius.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.